Welcome: Hangzhou Miu Instruments CO.LTD
Language: Chinese ∷  English

Industry new


"Dropping blood for cancer testing" has always been an important and difficult point in medical research. In the third China's "Internet +" College Students' innovation and entrepreneurship competition, which was just concluded soon, the early detection system of cancer in Southeast University's MxHealth team used the first and the world's leading photonic crystal microsphere technology to design an automatic testing instrument. It only needs 5 to 10 minutes to collect blood samples through the finger tip, which can complete 16 cancer screening and win the "Silver Award". It has aroused widespread concern in the industry.

Chang Ning, head of MxHealth team, told reporters that the self-developed automated detector uses multi-index joint detection, through the establishment and analysis of large data relationships of multiple tumor markers, so as to reduce the probability of false positive and false negative, and greatly improve the accuracy of detection. "Generally speaking, the instrument we developed is judged by fluorescence intensity. If the fluorescence in the patient's blood exceeds the warning value, he may have a cancer lesion in his body. He will be advised to have a detailed examination later.

What's the difference between the system and the traditional cancer detector? Reporters have learned that traditional cancer detection often uses a single indicator, aiming at a marker of a certain cancer, and the concentration of this marker will be affected by the user's mood, diet, environment and other factors, thus affecting the test results. In addition, the cost of cancer testing in hospitals is basically 50 yuan per index, and several tests need to be superimposed. "In clinical trials, our instrument can control the detection of 5-6 indicators below 100 yuan." Changning told reporters.

As this early detection instrument for cancer belongs to three categories of medical devices, it must apply to the State Food and Drug Administration (CFDA) for approval before it can enter the market. It is expected that it will take 2-3 years or even longer for the instrument to be put into the market. During this period, Dr. Changning and others will continuously optimize the functions of the instrument and improve the detection accuracy. I believe that in the near future, the concept of early cancer screening can be deeply rooted in the hearts of the people, do an early cancer detection and we check blood routine, blood pressure and blood sugar as common. By then, cancer will be less terrible.

Tumor markers are not the criteria for diagnosis of tumors, but play an alert role. Any examination should follow a step-by-step process from simple, non-invasive, inexpensive to complex, invasive and expensive. From suspicion to diagnosis, there must be sufficient examination and sufficient evidence. The research by Dr. Changning and others of Southeast University is quite prospective. Maybe there will be a drop of blood test for cancer in the future.


Contact: Phone: 17767139291

Tel: 0571-87653906

Email: sales@miulab.com


Add: 3F, Block 1, Deyu Building, 1418-3 Moganshan Road, Hangzhou, Zhejiang, China

Scan the qr codeClose
the qr code